According to the study “Small-Cell Lung Cancer – Pipeline Review, H1 2018”, the market for small cell lung cancer treatment is geographically spread across Americas, Europe, and Asia Pacific excluding Japan, Japan and Middle East & Africa. America accounts for better treatment options because it is a highly developed region with more healthcare facilities and more population are aware about small cell lung cancer. Asia Pacific and Europe countries are expecting a remarkable growth in the small cell lung cancer treatment market. According to World Health Organization (WHO) reports, more than 10 million people are affected with cancer which is one of the leading causes of death. The leading cancer type is lung cancer that accounts for the majority of the deaths. The leading key players of small-cell lung cancer market are AbbVie Inc, Advenchen Laboratories LLC, Aeglea BioTherapeutics Inc, Amgen Inc, Andarix Pharmaceuticals Inc, Aposense Ltd, Aprea AB, Ascentage Pharma Group Corp Ltd, Astellas Pharma Inc and others.
Cancer occurs due to cell transformation where normal cells grow and multiply without control. The common cause of mortality and morbidity worldwide is lung cancer that is caused majorly due to smoking. Lung cancer is categorized into two types such as non-small cell lung cancer and small cell lung cancer. Small cell lung cancer is caused due to smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer cannot be diagnosed at an early stage and can be diagnosed only at the late stage of disease progression leading to more number of deaths. Small cell lung cancer is recurrent in nature, spreads quickly and is difficult to cure at a go. This cancer usually starts in the breathing tubes (bronchi) in the center of the chest as tumors and often spread rapidly to the other parts of the human body, including brain, liver, and bone.
The major risk factors for small cell lung cancer are modernization, smoking, increased alcohol consumption, unhealthy food, air pollution, chronic infections, family history of lung cancer, HIV, exposure to triggers and carcinogens such as radon gas, exposure to radioactive materials, air pollution and no physical activity are indirectly driving the global small cell lung cancer market. All the emerging economies are providing awareness among the people about the small cell lung cancer. Various available treatments for small cell lung cancer are surgery, radiation therapy and chemotherapy. Surgery is performed to remove malignant tumor and lymph node in lungs. Chemotherapy treatment is given at an early stage of small cell lung cancer. Radiation therapy is given to shrink tumor cells, to relieve symptoms such as bleeding, cough, trouble swallowing and shortness of breath. Three-dimensional conformal radiation therapy (3D-CRT) and Intensity modulated radiation therapy (IMRT) are the two types of radiation methods used in small cell lung cancer treatment.
The pipeline review on small cell lung cancer market provides a comprehensive analysis on various key players, targeted therapeutics under development, drug target, mechanism of action (MoA), route of administration (RoA), molecule type, descriptive pharmacological action of the therapeutics, complete research and development history, summary of all the dormant and discontinued projects, latest news reports, press releases reports, thoughtful insights, facts, historical data, statistically supported industry-validated market data, a suitable set of assumptions and methodologies, geography, applications, market segments, market dynamics, market size, supply, demand, current trends/issues/challenges, competition, technology, value chain, in-depth analysis on new and available drugs, macro-economic indicators, governing factors along with market attractiveness, latest industry trends and developments. Global small cell lung cancer therapeutics market will witness an advance higher growth rate as compared to previous years due to increasing in instances of smoking, rising cases of lung infections, and increasing rate of lung cancers. Therefore, there will be an increasing demand for small cell lung cancer drugs over the next few years.
To know more, click on the link below:
Ankur Gupta, Head Marketing & Communications